China's Supply Chain Leverage: What Western De-Risking Efforts Miss | The Calibre Brief Ep. 42
About this episode
This episode of The Calibre Brief explores the true nature of China's supply chain leverage, challenging common assumptions about its origins and impact on global markets. While many believe China's dominance is due to its extensive mining operations, the episode reveals that the real control resides in the next stages: refining, separation, and precursor chemical processing.
Western efforts to de-risk supply chains have led to various strategies, including subsidies and stockpiling, but these operate on different timelines and have their own failure modes. Notably, Japan's decade-long diversification effort offers both successes and limitations, reducing its rare earth dependency on China but not eliminating it.
The 2025 export controls by China have resulted in significant price hikes for key minerals, showcasing the impact of midstream chokepoint control. Yet, the debate continues on whether Western de-risking efforts are achieving their aim or merely relocating addresses on invoices. This episode seeks to clarify these complex dynamics and what truly constitutes effective de-risking in the face of existing chokepoints.
Key topics
Key moments
- 0:07 Rare earths are mined in Australia, Chile, and Congo
- 0:26 By 2025, Chinese export controls sent prices sharply higher across…
- 1:08 Extraction is partially diversified
- 1:57 The assumption that diversifying purchase orders toward allied…
- 3:04 What the evidence actually supports is not a binary outcome but a…
- 3:42 China's leverage lives in the midstream processing infrastructure…
- 4:04 If you want to continue this conversation, search The Calibre Brief…
Transcript
Show transcript
Welcome to The Calibre Brief, a Calibre Code USA production.
Rare earths are mined in Australia, Chile, and Congo. China is not the dominant extractor. The dominant refiner, the dominant separator, the dominant precursor chemist. That distinction is where the strategic question lives.
By 2025, Chinese export controls sent prices sharply higher across European markets. Gallium rose 365 percent. Germanium climbed 400 percent. Antimony surged 437 percent. These are not abstract statistics. Gallium compounds feed radar systems and LED lighting. Germanium is in missile guidance optics. Antimony stabilizes flame-retardant coatings inside aircraft cabins and hospital firewalls. The escalation showed in the price data before any policy statement confirmed it. The signal had become a mechanism.
Extraction is partially diversified. Australia mines rare earths. Chile produces lithium. Congo refines cobalt. What is not diversified is the refining, separation, and precursor chemistry that turns raw material into usable input. The International Energy Agency documents that China controls roughly 90 percent of global rare earth processing capacity, about three-quarters of cobalt refining, nearly two-thirds of lithium processing. The picture repeats in pharmaceuticals. China supplies the raw starting materials for 94 percent of amoxicillin, 74 percent of heparin, and 70 percent of acetaminophen consumed in the United States. The leverage is in the refinery, not the mine.
The assumption that diversifying purchase orders toward allied suppliers reduces Chinese leverage encounters a documented problem. When researchers traced where those orders actually went, materials had been rerouted through Chinese midstream facilities and repackaged in third countries. The chokepoint had not moved. Japan's ten-year effort, backed by government equity stakes in Australian producers, recycling research, and stockpile building, reduced its Chinese rare earth dependency from roughly 90 percent to 60 percent. That is what determined policy achieved. The timelines compound the constraint. The CHIPS Act's 52.7 billion dollar commitment buys three to five years from construction decision to high-volume output. The IEA estimates mineral projects take over 16 years from discovery to first production. The October 2025 truce did not dismantle the licensing infrastructure Beijing built. The coercive option remains.
What the evidence actually supports is not a binary outcome but a layered set of tools operating on different timelines and carrying different failure modes. The processing infrastructure behind these percentages cannot be replicated overnight. Western policy has chosen to build allied capacity rather than remain permanently exposed, accepting costs measured in years and decades rather than policy cycles. The window the truce opened for Western financing and construction is the asset worth examining.
China's leverage lives in the midstream processing infrastructure, not the extraction stage. Diversification that continues to funnel through that infrastructure is diversification in name only. Real de-risking requires targeting the specific chokepoint, not the country on an invoice.
If you want to continue this conversation, search The Calibre Brief on YouTube and leave a comment. What metric distinguishes actual chokepoint-stage diversification from a change in invoice address? And who verifies it? Follow the podcast for more.
